See K - Search Results

1

Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.

Blauvelt A, Muram TM, See K, Mallinckrodt CH, Crowley JJ, van de Kerkhof P. Blauvelt A, et al. Among authors: see k. J Dermatolog Treat. 2018 May;29(3):220-229. doi: 10.1080/09546634.2017.1365114. Epub 2017 Sep 29. J Dermatolog Treat. 2018. PMID: 28792259 Free article. Clinical Trial.

2

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.

Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB. Blauvelt A, et al. Among authors: see k. J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1004-1013. doi: 10.1111/jdv.14163. Epub 2017 Mar 31. J Eur Acad Dermatol Venereol. 2017. PMID: 28190255 Free PMC article. Clinical Trial.

3

Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab.

Warren RB, Brnabic A, Saure D, Langley RG, See K, Wu JJ, Schacht A, Mallbris L, Nast A. Warren RB, et al. Among authors: see k. Br J Dermatol. 2018 May;178(5):1064-1071. doi: 10.1111/bjd.16140. Epub 2018 Mar 1. Br J Dermatol. 2018. PMID: 29171861

4

Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice.

Merola JF, Amato DA, See K, Burge R, Mallinckrodt C, Ojeh CK, Gottlieb A. Merola JF, et al. Among authors: see k. J Invest Dermatol. 2018 Sep;138(9):1955-1961. doi: 10.1016/j.jid.2018.01.041. Epub 2018 Mar 22. J Invest Dermatol. 2018. PMID: 29577919 Free article. Clinical Trial.

5

Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial.

Blauvelt A, Lebwohl MG, Mabuchi T, Leung A, Garrelts A, Crane H, ElMaraghy H, Patel H, Ridenour T, See K, Gallo G, Paul C. Blauvelt A, et al. Among authors: see k. J Am Acad Dermatol. 2021 Aug;85(2):360-368. doi: 10.1016/j.jaad.2020.11.022. Epub 2020 Nov 28. J Am Acad Dermatol. 2021. PMID: 33253833 Free article. Clinical Trial.

6

Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial.

Ryan C, Guenther L, Foley P, Weisman J, Burge RT, Gallo G, See K, McKean-Matthews M, Bertram CC, Merola JF. Ryan C, et al. Among authors: see k. J Eur Acad Dermatol Venereol. 2022 Apr;36(4):e277-e279. doi: 10.1111/jdv.17836. Epub 2021 Dec 4. J Eur Acad Dermatol Venereol. 2022. PMID: 34812561 Free PMC article. Clinical Trial. No abstract available.

7

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis.

Leonardi CL, See K, Burge R, Sun Z, Zhang Y, Mallbris L, Garrelts A, Warren RB. Leonardi CL, et al. Among authors: see k. Adv Ther. 2022 May;39(5):2256-2269. doi: 10.1007/s12325-022-02065-w. Epub 2022 Mar 22. Adv Ther. 2022. PMID: 35316500 Free PMC article.

8

Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks.

Egeberg A, Kristensen LE, Puig L, Rich P, Smith SD, Garrelts A, See K, Holzkaemper T, Fotiou K, Schuster C. Egeberg A, et al. Among authors: see k. J Dermatolog Treat. 2023 Dec;34(1):2263108. doi: 10.1080/09546634.2023.2263108. Epub 2023 Oct 2. J Dermatolog Treat. 2023. PMID: 37781881 Free article.

9

Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas.

Gottlieb AB, Armstrong A, Blauvelt A, Griffiths CEM, Pinter A, Gooderham M, Lomaga M, Burge RT, Konicek BW, McDonald MF, See K, McKean-Matthews M, Mabuchi T. Gottlieb AB, et al. Among authors: see k. J Drugs Dermatol. 2024 Aug 1;23(8):619-625. doi: 10.36849/JDD.8160. J Drugs Dermatol. 2024. PMID: 39093657 Clinical Trial.

10

Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis.

Grace E, Goldblum O, Renda L, Agada N, See K, Leonardi C, Menter A. Grace E, et al. Among authors: see k. Dermatol Ther (Heidelb). 2020 Feb;10(1):99-106. doi: 10.1007/s13555-019-00341-2. Epub 2019 Nov 16. Dermatol Ther (Heidelb). 2020. PMID: 31734937 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

298 results

Search Page

Filters